Recombinant Mouse Anti-Influenza A Antibody (S139) (CAT#: PABX-118)

Figure 1 SDS-PAGE analysis of purified S139/1 IgA and IgG antibodies.

Equal amounts (2.5 mg) of purified S139/1 IgA and IgG antibodies were analyzed by SDS-PAGE under reducing conditions (5%–20% gradient gel) (A). Polymeric forms of purified S139/1 IgA and IgG antibodies (5 mg) were analyzed under nonreducing conditions (3%–10% gradient gel) (B).

Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., ... & Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One, 9(1), e85582.

Figure 2 Comparison of binding activities of S139/1 IgA and IgG antibodies.

Binding activities of S139/1 IgA (continuous lines) and IgG (dashed lines) were tested in ELISA. Disrupted viral particles of Aichi/H3, WSN/H1, Adachi/H2, and Maryland/H13 were used as antigens. Data are mean values of duplicate wells. EC50 values calculated based on the ELISA data are shown in Table 1.

Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., ... & Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One, 9(1), e85582.

Figure 3 Comparison of neutralizing activities of S139/1 IgA and IgG antibodies.

Appropriately diluted viruses were mixed with S139/1 IgA (continuous lines) or IgG (dashed lines) at the indicated dilutions. Neutralizing activities were evaluated by counting the number of plaques formed on MDCK cells. IC50 values calculated based on the neutralization curves are shown in Table 3.

Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., ... & Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One, 9(1), e85582.